Literature DB >> 22090423

Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.

Fredrik H Sterky1, Alexander F Hoffman, Dusanka Milenkovic, Betty Bao, Arianna Paganelli, Daniel Edgar, Rolf Wibom, Carl R Lupica, Lars Olson, Nils-Göran Larsson.   

Abstract

A variety of observations support the hypothesis that deficiency of complex I [reduced nicotinamide-adenine dinucleotide (NADH):ubiquinone oxidoreductase] of the mitochondrial respiratory chain plays a role in the pathophysiology of Parkinson's disease (PD). However, recent data from a study using mice with knockout of the complex I subunit NADH:ubiquinone oxidoreductase iron-sulfur protein 4 (Ndufs4) has challenged this concept as these mice show degeneration of non-dopamine neurons. In addition, primary dopamine (DA) neurons derived from such mice, reported to lack complex I activity, remain sensitive to toxins believed to act through inhibition of complex I. We tissue-specifically disrupted the Ndufs4 gene in mouse heart and found an apparent severe deficiency of complex I activity in disrupted mitochondria, whereas oxidation of substrates that result in entry of electrons at the level of complex I was only mildly reduced in intact isolated heart mitochondria. Further analyses of detergent-solubilized mitochondria showed the mutant complex I to be unstable but capable of forming supercomplexes with complex I enzyme activity. The loss of Ndufs4 thus causes only a mild complex I deficiency in vivo. We proceeded to disrupt Ndufs4 in midbrain DA neurons and found no overt neurodegeneration, no loss of striatal innervation and no symptoms of Parkinsonism in tissue-specific knockout animals. However, DA homeostasis was abnormal with impaired DA release and increased levels of DA metabolites. Furthermore, Ndufs4 DA neuron knockouts were more vulnerable to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Taken together, these findings lend in vivo support to the hypothesis that complex I deficiency can contribute to the pathophysiology of PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090423      PMCID: PMC3277308          DOI: 10.1093/hmg/ddr537

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  41 in total

1.  Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

Authors:  Mats I Ekstrand; Mügen Terzioglu; Dagmar Galter; Shunwei Zhu; Christoph Hofstetter; Eva Lindqvist; Sebastian Thams; Anita Bergstrand; Fredrik Sterky Hansson; Aleksandra Trifunovic; Barry Hoffer; Staffan Cullheim; Abdul H Mohammed; Lars Olson; Nils-Göran Larsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

2.  Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain.

Authors:  N W Soong; D R Hinton; G Cortopassi; N Arnheim
Journal:  Nat Genet       Date:  1992-12       Impact factor: 38.330

3.  Mitochondrial function in Parkinson's disease.

Authors:  L A Bindoff; M Birch-Machin; N E Cartlidge; W D Parker; D M Turnbull
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

4.  Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.

Authors:  Vesna Sossi; Raúl de La Fuente-Fernández; James E Holden; Doris J Doudet; Jess McKenzie; A J Stoessl; T J Ruth
Journal:  J Cereb Blood Flow Metab       Date:  2002-02       Impact factor: 6.200

5.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

6.  Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.

Authors:  Cameron H Good; Alexander F Hoffman; Barry J Hoffer; Vladimir I Chefer; Toni S Shippenberg; Cristina M Bäckman; Nils-Göran Larsson; Lars Olson; Sandra Gellhaar; Dagmar Galter; Carl R Lupica
Journal:  FASEB J       Date:  2011-01-13       Impact factor: 5.191

7.  Mitochondrial complex III stabilizes complex I in the absence of NDUFS4 to provide partial activity.

Authors:  Maria Antonietta Calvaruso; Peter Willems; Mariël van den Brand; Federica Valsecchi; Shane Kruse; Richard Palmiter; Jan Smeitink; Leo Nijtmans
Journal:  Hum Mol Genet       Date:  2011-09-28       Impact factor: 6.150

8.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

9.  MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.

Authors:  D Galter; K Pernold; T Yoshitake; E Lindqvist; B Hoffer; J Kehr; N-G Larsson; L Olson
Journal:  Genes Brain Behav       Date:  2009-10-07       Impact factor: 3.449

10.  VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation.

Authors:  Carolina Birgner; Karin Nordenankar; Martin Lundblad; José Alfredo Mendez; Casey Smith; Madeleine le Grevès; Dagmar Galter; Lars Olson; Anders Fredriksson; Louis-Eric Trudeau; Klas Kullander; Asa Wallén-Mackenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

View more
  36 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 3.  Mitochondrial Diseases Part I: mouse models of OXPHOS deficiencies caused by defects in respiratory complex subunits or assembly factors.

Authors:  Alessandra Torraco; Susana Peralta; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-02-04       Impact factor: 4.160

4.  Impaired complex IV activity in response to loss of LRPPRC function can be compensated by mitochondrial hyperfusion.

Authors:  Stéphane G Rolland; Elisa Motori; Nadin Memar; Jürgen Hench; Stephan Frank; Konstanze F Winklhofer; Barbara Conradt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

5.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

6.  Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.

Authors:  Fredrik H Sterky; Karin Pernold; Brandon K Harvey; Eva Lindqvist; Barry J Hoffer; Lars Olson
Journal:  Cell Transplant       Date:  2012-10-08       Impact factor: 4.064

7.  MPTP's pathway of toxicity indicates central role of transcription factor SP1.

Authors:  Alexandra Maertens; Thomas Luechtefeld; Andre Kleensang; Thomas Hartung
Journal:  Arch Toxicol       Date:  2015-04-08       Impact factor: 5.153

Review 8.  Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain.

Authors:  James A Letts; Leonid A Sazanov
Journal:  Nat Struct Mol Biol       Date:  2017-10-05       Impact factor: 15.369

9.  Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.

Authors:  Hyung-Wook Kim; Won-Seok Choi; Noah Sorscher; Hyung Joon Park; François Tronche; Richard D Palmiter; Zhengui Xia
Journal:  Neurobiol Aging       Date:  2015-05-16       Impact factor: 4.673

Review 10.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.